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We attached the pathogen associated molecular pattern
Kdo2-Lipid A (the lipopolysaccharide (LPS) from Escherichia
coli (E. coli)) to QDs by hydrophobic interactions to synthetically
mimic the surface of E. coli. QD-LPS conjugates bind, are taken
up and activate eﬀectively macrophages in vitro and they have
potent immunostimulatory activity in vivo.
Biological chemistry uses many types of small synthetic
molecules to probe and understand facets of biology. Important
examples include the range of organic dyes which as ﬂuorescent
probes enable the behaviour of individual biomolecules to be
tracked in vitro and in vivo.1 Also important are synthetic
compounds which, resembling the structures and functions
of active sites, provide a chemical approach to understand
enzyme catalysis.2 However, it is important that we progressively
move to understanding more complex biological systems and,
for this, new nanomaterials oﬀer unique opportunities.
Colloidal quantum dots (QDs) have become important
materials in biology as alternatives to traditional organic
and genetically-encoded ﬂuorophores due to their unique
optical properties.3 So far they have been used to track
individual biomolecules, but for this application a widespread
concern is that biomolecules can lose activity when they are
attached to QDs because these are multivalent and large.4
Thus, recent attention has turned toward labeling strategies
which enable site-speciﬁc recognition5 and controlling the
number of molecules that can be attached to a single QD
down to a single molecule.6 However, multivalency is important
for regulating a wide range of biological processes.7 It has been
shown that the ability of multivalent ligands to cluster cell
surface receptors for the initiation of downstream signal
transduction responses can lead to increased activity over
monovalent ligands.7 Thus, the nanometre-size and multi-
valency of QDs can become useful features for some applications,
as some studies are beginning to show.3e,8
Attachment of pathogen associated molecular patterns
(PAMPs; evolutionary conserved, pathogen-derived motifs
which the host uses to discriminate self from non-self9) to
QDs opens up the door to synthetic mimics of bacteria and
viruses. The creation of these new tools will enable us to
elucidate how microbial pathogens are processed by the
immune system, and therefore to gain new perspectives on
how to combat infectious diseases more eﬀectively. Here we
focus on lipopolysaccharides (LPS)—a PAMP which decorates
the surface of Gram-negative bacteria. Immune responses to
LPS play a key role in septic shock—the most common cause
of mortality in intensive care units worldwide10—and can be
tailored to give clinically useful immune responses to enhance
the eﬃciency of vaccines.11 The primary immunostimulatory
component of LPS is the lipid A core (also known as endotoxin,
Fig. 1), which activates Toll like receptor 4 (TLR4) on the
extracellular side of the membrane of cells of the innate
immune system. TLR4 is required for signaling through a
group of Toll/interleukin-1 receptor (TIR)-adaptors (TIRAP,
MyD88, TRIF and TRAM).12 However, it is known that
other receptors are involved in LPS-induced cell activation
and that these form receptor clusters. LPS binding protein
(LBP), CD14, MD2, the macrophage scavenger receptor
(SR-A) and b2 leukocyte integrins CD11b/CD18 have been
shown to participate in LPS-induced cell activation.12,13 LPS
has amphipathic properties, and although it varies among
diﬀerent bacterium in most cases, two 2-keto-3-deoxyoctonate
(kdo) units are linked to lipid A (Fig. 1). Recently, we
discovered that metal surfaces decorated with long-chain
hydrophobic molecules can act as eﬀective pattern recognition
receptors for the hydrophobic core of LPS for electrochemical
detection of LPS.14 Here we attach LPS to QDs by hydro-
phobic interactions to synthetically mimic the surface of
Escherichia coli (E. coli) with a brightly ﬂuorescent and
chemically controllable nanoparticle (Fig. 1). We show that
the QD-LPS conjugates bind, are taken up and activate
eﬀectively antigen presenting cells and have potent immuno-
stimulatory activity in vivo.
Kdo2-lipid A (pure E. coli LPS) was attached to core-shell
CdSe-ZnS QDs coated with stearic acid—a non-toxic naturally
produced fatty acid commonly used in pharmaceuticals and
cosmetics. These QDs showed an absorption peak due to the
ﬁrst excitonic transition at 628 nm and a photoluminescence
maximum at 642 nm (fwhm = 42 nm) and had a diameter of
B5.8 nm. By high-resolution transmission electron micro-
scopy (HRTEM) the QDs appeared nanocrystalline and
mostly spherical in shape (Fig. S1, ESIz). QD-LPS micelles
were prepared by mixing the hydrophobic QDs with excess of
Kdo2-lipid A by self-assembly of the biopolymer chains
around the QD hydrophobic core (see ESIz). Dynamic light
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scattering (DLS) studies revealed that the QD-LPS micelles
are between 11 and 15 nm in diameter in solution (Fig. S2,
ESIz). This result correlates nicely with the size of the QD (the
5.8 nm of the semiconductor nanocrystal and 2  2.0 nm
due to stearic acid gives a spherical particle of 9.8 nm) and
Kdo2-lipid A (3 nm).
15
Confocal microscopy studies revealed that after 30 min
incubation QD-LPS micelles (10 nM) at 37 1C had been taken
up by macrophages (mouse macrophage cell line J774,
Fig. 2A), presumably by receptor induced endocytosis (for
LPS, a clathrin-mediated process).16 In contrast, control QD
micelles containing n-poly(ethyleneglycol) phosphatidylethanol-
amine (PEG-PE) did not bind, and those containing PEG-PE
and the naturally occurring phospholipid phosphatidylcholine
(PC) did bind but were taken up more slowly even at higher
concentrations (Fig. S3, ESIz). Flow cytometric analysis of the
macrophages co-cultured with the QD-LPS micelles for 3 h
conﬁrmed QD-LPS binding, even at the low concentration of
0.65 nM (Fig. 2B).
We tested the immunostimulatory activity of the QD-LPS
micelles with the mouse macrophage cell line J774 and
bone-marrow derived dendritic cells (BMDCs) from wild-type
mice. Controls we used were PBS, uncoupled Kdo2-lipid A
and PC and PEG-PE coated QDs.17 After incubation for
16–24 h, supernatants were harvested and cytokine IL-6, a
pro-inﬂammatory cytokine secreted by macrophages and
BMDCs upon PAMP stimulation,18 was quantiﬁed by ELISA.
Remarkably, cytokine production for macrophages treated
with 1.5 nM QD-LPS conjugates was higher than with
250 nM LPS alone (1/10 dilution, Fig. 3A), and similar for
BMDCs (Fig. 3B). If we consider the dimensions of Kdo2-lipid
A15 (surface area ofB2 nm2) and that the QD at the point of
interaction with the LPS chains has a radius of 4 nm, then a
QD cannot hold more than 100 LPS molecules. The actual
number of LPS molecules per QD was determined using the
zinc dipicolylamine (Zn-DPA) complex which Hamachi
et al.19 originally developed for ﬂuorescence detection of
phosphorylated peptides (see ESIz). Recent studies have
shown that this zinc complex selectively targets and ﬂuorescently
labels the surface of bacterial cell walls and LPS-modiﬁed
surfaces via recognition of the anionic phosphate esters of
LPS.14,20 The QD-LPS micelles used in this study captured ca.
130 molecules of this phosphate binding zinc(II) complex
(see ESIz). Because each Kdo2-lipid A has two dianionic
phosphate ester groups, we estimate that these QDs therefore
carry around 65 LPS molecules each. Thus, the immuno-
stimulatory activity of QD-LPS micelles is considerably greater
than that of LPS as 0.15 nM QD-LPS shows more potent IL-6
induction than 250 nM LPS alone. Release of cytokines was
strongly inhibited by the LPS antagonist polymyxin B (PMB),
and control QDs lacked any activity; thus the immuno-
stimulatory properties of the QD-LPS micelles are LPS-induced.
Similar results were seen with TNF-a (data not shown);
another cytokine secreted by macrophages following their
stimulation with LPS.
To determine if the potent immunomodulatory activity of
QD-LPS micelles observed in vitro translated to in vivo
immune responses we carried out a series of immunisations.
Groups of ﬁve mice were immunised intraperitoneally (i.p.)
with dinitrophenylated-ovalbumin (DNP-OVA) as model
antigen, alone and co-administered with LPS, QD-LPS
micelles and sub-cutaneously (s.c.) administered LPS in
incomplete Freund’s adjuvant (IFA is a widely used and
potent adjuvant).21 Mice were bled before immunisation and
at 7 day intervals, and anti-DNP serum antibodies quantiﬁed
by indirect ELISA. We quantiﬁed total antibodies and the
isotypes IgG2c and IgG1. In the immune response to an
injected antigen in mice and humans CD4+ T helper cells
1 and 2 (Th1 and Th2) play an important role and can have a
signiﬁcant impact on the overall protection a vaccine provides.22
In mice production of IgG2c is recognized as characteristic of
Fig. 1 Analogy between E. coli and LPS (Kdo2-lipid A)-coated QDs.
Fig. 2 (A) Confocal images of J774 macrophages after staining with
Hoechst 33342 (blue, nuclei) and DiOC18 (green, membrane) at 5 min,
35 min, and 65 min after beginning incubation with 10 nM QD-LPS
(red) containing medium at 37 1C (top). The 3D reconstituted images
of the cell marked with an arrow (bottom). (B) Flow cytometry
analysis of macrophages before (black) and after incubation with
QD-LPS (0.65 nM, red line; 65 pM, blue line).













































a Th1 immune response,23 whereas a Th2 response is associated
with the induction of IgG1. The QD-LPS conjugates (10 pmol
of QD,B1.5 mg of LPS based on 65 molecules of LPS per QD)
showed the highest adjuvant potency (i.e. ability to improve
the immune response to vaccine antigens); greater than LPS
alone (4 mg) and even than LPS isolated from E. coli (10 mg)
emulsiﬁed in IFA (Fig. 4). Attachment of LPS to QDs
enhances its immunostimulatory activity in vivo, acting as a
potent adjuvant. No signs of toxicity were detected over the
3–4 months following immunization. The demonstration that
QD-LPS has potent adjuvant activity, even at low LPS doses,
is an exciting one as ﬁnding new adjuvants has become an
important target and bottleneck in vaccine development.21
In summary, we have attached Kdo2-lipid A to QDs to
synthetically mimic the surface of E. coli with a brightly
ﬂuorescent nanomaterial. The immunostimulatory activity of
this important biomolecule was found to be higher attached to
the QD than alone, both in vitro and in vivo. Although many
diﬀerent types of biomolecules have been attached to QDs, we
are not aware of another study in which biological activity
increased by attachment to QDs. Despite the focus being on
LPS and micelles which are smaller than typical pathogens, it
is clear that other microbial products can be attached to QDs
and that several QDs can be self-assembled to form larger
structures. In doing so, it should be possible to better mimic
the multivalency and ‘cocktail’ of biomolecules encountered
by the immune system when interacting with microbial pathogens
in vivo. Thus, we anticipate that QD-PAMP conjugates could
become important model materials to investigate how bacteria
and viruses interact and are processed by the immune system,
and to learn how to ﬁght infectious diseases more eﬀectively.
We are continuing our studies to develop synthetic materials
which can be easily tracked in vitro and in vivo and are capable
of setting oﬀ the alarms of the immune system in a predictable
way because of their biological cargos.
Experiments were covered by a Project License granted by
the Home Oﬃce under the Animal (Scientiﬁc Procedures) Act
1986. This license was approved locally by the Universities of
Edinburgh and Cambridge Ethical Review Committees.
We are grateful to Cancer Research UK and EaStCHEM
for PhD studentships to M.K. and M.G. The work was
partially funded by a grant to D.G. from the Wellcome Trust
and a Moray Endowment Award to J.C.M-R. We thank Dr
Wuzong Zhou and Ross Blackley for the HRTEM studies,
and Dr David Kelly for help with the confocal studies.
Notes and references
1 (a) J. Zhang, R. E. Campbell, A. Y. Ting and R. Y. Tsien, Nat.
Rev. Mol. Cell Biol., 2002, 3, 906; (b) R. P. Haugland, The
Handbook—A Guide to Fluorescent Probes and
Labeling Technologies, Molecular Probes, Eugene, 10th edn, 2005.
2 (a) R. Breslow, Acc. Chem. Res., 1995, 28, 146; (b) A. J. Kirby and
F. Hollfelder, From Enzyme Models to Model Enzymes, RSC
Publishing, Cambridge, 2009.
Fig. 3 (A) IL-6 release from macrophages treated at 1/10 dilution
with: [QD-LPS] = 1.5 nM; [LPS] = 250 nM; [control QD] = 2.5 nM.
PMB is the LPS inhibitor polymyxin B; [PMB] = 250 mM. PBS =
phosphate-buﬀered saline, pH 7.4. The control QD is coated with PC
and PEG-PE. Incubation time = 16 h. (B) IL-6 release from
bone-marrow derived dendritic cells from wild-type mice treated at
1/10 dilution with: [QD-LPS] = 1.5 nM; [LPS] = 250 nM; [control
QD] = 2.5 nM. PMB is the LPS inhibitor polymyxin B; [PMB] =
250 mM. PBS = phosphate-buﬀered saline, pH 7.4. The control QD is
coated with PC and PEG-PE. Incubation time = 24 h.
Fig. 4 Antibody (Ab) responses (total Ab, IgG1 and IgG2c) to
antigen (DNP-OVA, 100 mg) alone and co-administered (i.p.) with
QD-LPS (10 pmol), LPS (4 mg) and E. coli LPS (10 mg) emulsiﬁed in
IFA (s.c. injected); boosting with DNP-OVA after 56 days. Values
plotted are means based on titers from ﬁve individual mice and
representative of two diﬀerent experiments.













































3 (a) X. Michalet, F. F. Pinaud, L. A. Bentolila, J. M. Tsay,
S. Doose, J. J. Li, G. Sundaresan, A. M. Wu, S. S. Gambhir and
S. Weiss, Science, 2005, 307, 538; (b) X. Gao, L. Yang, J. A. Petros,
F. F. Marshall, J. W. Simons and S. Nie, Curr. Opin. Biotechnol.,
2005, 16, 63; (c) I. L. Medintz, H. T. Uyeda, E. R. Goldman and
H. Mattoussi, Nat. Mater., 2005, 4, 435; (d) U. Resch-Genger,
M. Grabolle, S. Cavaliere-Jaricot, R. Nitschke and T. Nann, Nat.
Methods, 2008, 5, 763; (e) D. S. Lidke, P. Nagy, R. Heintzmann,
D. J. Arndt-Jovin, J. N. Post, H. E. Grecco, E. A. Jares-Erijman
and T. M. Jovin, Nat. Biotechnol., 2004, 22, 198.
4 (a) W. J. Parak, T. Pellegrino and C. Plank, Nanotechnology, 2005,
16, R9; (b) Q. Huo, Colloids Surf., B, 2007, 59, 1; (c) M. Howarth,
W. Liu, S. Puthenveetil, S. Zheng, L. F. Marshall, M. M. Schmidt,
K. D. Wittrup, M. G. Bawendi and A. Y. Ting, Nat. Methods,
2008, 5, 397.
5 (a) Y. Zhang, M. K. So, A. M. Loening, H. Yao, S. S. Gambhir
and J. Rao, Angew. Chem., Int. Ed., 2006, 45, 4936; (b) I. Chen,
M. Howarth, W. Lin and A. Y. Ting, Nat. Methods, 2005, 2, 99;
(c) M. Gupta, A. Caniard, A. Touceda-Varela, D. J. Campopiano
and J. C. Mareque-Rivas, Bioconjugate Chem., 2008, 19, 1964;
(d) J. Kim, H. Y. Park, J. Kim, J. Ryu, Y. Kwon, R. Grailhe and
R. Song, Chem. Commun., 2008, 1910.
6 R. A. Sperling, T. Pellegrino, J. K. Li, W. A. Chang and
W. J. Parak, Adv. Funct. Mater., 2006, 16, 943.
7 (a) M. Mammen, S.-K. Choi and G. M. Whitesides, Angew. Chem.,
Int. Ed., 1998, 37, 2754; (b) L. L. Kiessling, J. E. Gestwicki and
L. E. Strong, Curr. Opin. Chem. Biol., 2000, 4, 696;
(c) C. R. Bertozzi and L. L. Kiessling, Science, 2001, 291,
2357.
8 (a) G. Mene´ndez, M. J. Roberti, V. Sigot, M. Etchehon,
T. M. Jovin and E. A. Jares-Erijman, Proc. SPIE, 2009, 7189,
71890P; (b) M. J. Roberti, M. Morgan, G. Menendez,
L. I. Pietrasanta, T. M. Jovin and E. A. Jares-Erijman, J. Am.
Chem. Soc., 2009, 131, 8102.
9 (a) L. A. O’Neill, Curr. Opin. Immunol., 2006, 18, 3; (b) K. Oda and
H. Kitano, Mol. Syst. Biol., 2006, 2, 2006.0015.
10 (a) B. Beutler and E. T. Rietschel,Nat. Rev. Immunol., 2003, 3, 169;
(b) J. Cohen, Nature, 2002, 420, 885.
11 V. Mata-Haro, C. Cekic, M. Martin, P. M. Chilton, C. R. Casella
and T. C. Mitchell, Science, 2007, 316, 1628.
12 C. Watts, Nat. Immunol., 2008, 9, 343.
13 (a) R. Y. Hampton, D. T. Golenbock, M. Penman, M. Krieger and
C. R. Raetz, Nature, 1991, 352, 342; (b) L. Peiser, P. J. Gough,
T. Kodama and S. Gordon, Infect. Immun., 2000, 68, 1953;
(c) R. R. Ingalls, B. G. Monks, R. Savedra, W. J. Christ,
R. L. Delude, A. E. Medvedev, T. Espevik and
D. T. Golenbock, J. Immunol., 1998, 161, 5413.
14 V. Ganesh, K. Bodewits, S. F. Bartholdson, D. Natale,
D. J. Campopiano and J. C. Mareque-Rivas, Angew. Chem., Int.
Ed., 2009, 48, 356.
15 S. Obst, M. Kastowsky and H. Bradaczek, Biophys. J., 1997, 72, 1031.
16 H. Husebye, Ø. Halaas, H. Stenmark, G. Tunheim, Ø. Sandanger,
B. Bogen, A. Brech, E. Latz and T. Espevik, EMBO J., 2006, 25,
683.
17 (a) B. Dubertret, P. Skourides, D. J. Norris, A. H. Noireaux,
A. H. Brivanlou and A. Libchaber, Science, 2002, 298, 1759;
(b) O. Carion, B. Mahler, T. Pons and B. Dubertret, Nat. Protoc.,
2007, 2(10), 2383.
18 (a) T. Kishimoto, S. Akira and T. Taga, Science, 1992, 258, 593;
(b) I. Zanoni, R. Ostuni, G. Capuano, M. Collini, M. Caccia,
A. E. Ronchi, M. Rochetti, F. Mingozzi, M. Foti, G. Chirico,
B. Costa, A. Zara, P. Ricciardi-Castagnoli and F. Granucci,
Nature, 2009, 460, 264.
19 (a) A. Ojida, Y. Mito-oka, M.-A. Inoue and I. Hamachi, J. Am.
Chem. Soc., 2002, 124, 6256; (b) S. Yamaguchi, I. Yoshimura,
T. Kohira, S.-I. Tamaru and I. Hamachi, J. Am. Chem. Soc., 2005,
127, 11835.
20 (a) W. M. Leevy, J. R. Johnson, C. Lakshmi, J. Morris,
M. Marquez and B. D. Smith, Chem. Commun., 2006, 1595;
(b) J. R. Johnson, N. Fu, E. Arunkumar, W. M. Leevy,
S. T. Gammon, D. Piwnica-Worms and B. D. Smith, Angew.
Chem., Int. Ed., 2007, 46, 5528.
21 A. Pashine, N.M. Valiante and J. B. Ulmer,Nat. Med., 2005, 11, S63.
22 M. Singh and D. O’Hagan, Nat. Biotechnol., 1999, 17, 1075.
23 R. M. Martin, J. L. Brady and A. M. Lew, J. Immunol. Methods,
1998, 212, 187.
This journal is c The Royal Society of Chemistry 2010 Mol. BioSyst., 2010, 6, 1572–1575 | 1575
Pu
bl
ish
ed
 o
n 
20
 A
pr
il 
20
10
. D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 o
f E
di
nb
ur
gh
 o
n 
28
/0
5/
20
13
 1
2:
02
:0
4.
 
View Article Online
